leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 04:51:18 - browse：1

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Hospitals warn Medicare's drug payment fix is ‘unlawful’

WSS

Biden's order seeks to regulate AI risk without stifling innovation

Readout Newsletter: What happened with Sarepta's Duchenne data

Diversifying clinical trials isn't enough to close racial gaps: study

Diversifying clinical trials isn't enough to close racial gaps: study

Why Sanofi got shellacked over its spinoff

Telehealth options flood the market as retailers push virtual care

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Emergency medicine has repudiated 'excited delirium.' Now what?

Medical records are filled with copy

Why Sanofi got shellacked over its spinoff

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: XBI biotech index, Akero Therapeutics

Cancer drug shortages should be causing more outrage

Biden's order seeks to regulate AI risk without stifling innovation

Medical leaders decry Supreme Court decision on affirmative action

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

explore

Senate panel to vote on hospitals, PBMs, prisoner care

Cassava reveals details — and problems — with Alzheimer's study

Paying for Covid pills will soon shift to insurers

Biden's order seeks to regulate AI risk without stifling innovation

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Readout Newsletter: New research from Sanofi, Regeneron, etc.

leisure time

hotspot

Wikipedia

explore